Skip to main content
Top
Published in: Reactions Weekly 1/2024

01-02-2024 | Mepolizumab | Case report

Mepolizumab

Aggressive and invalidating atopic dermatitis

Published in: Reactions Weekly | Issue 1/2024

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Sabbe M, et al. When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report. Journal of Medical Case Reports 18 : 1-8, Jan 2024. Available from: URL: https://dx.doi.org/10.1186/s13256-023-04255-8 Sabbe M, et al. When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report. Journal of Medical Case Reports 18 : 1-8, Jan 2024. Available from: URL: https://​dx.​doi.​org/​10.​1186/​s13256-023-04255-8
Metadata
Title
Mepolizumab
Aggressive and invalidating atopic dermatitis
Publication date
01-02-2024
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2024
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-53587-z

Other articles of this Issue 1/2024

Reactions Weekly 1/2024 Go to the issue

Case report

Etanercept

Case report

BCG

Case report

Multiple drugs